Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UM22
UPID:
EPDR1_HUMAN
Alternative names:
Upregulated in colorectal cancer gene 1 protein
Alternative UPACC:
Q9UM22; A8K4C0; C9JYS3; Q06BL0; Q99M77
Background:
Mammalian ependymin-related protein 1, also known as Upregulated in colorectal cancer gene 1 protein, plays a crucial role in cellular processes by binding anionic lipids and gangliosides at acidic pH. This unique ability highlights its importance in the cellular environment, particularly in the modulation of membrane dynamics and signaling pathways.
Therapeutic significance:
Understanding the role of Mammalian ependymin-related protein 1 could open doors to potential therapeutic strategies. Its specific interaction with anionic lipids and gangliosides suggests a pivotal role in cellular communication and disease mechanisms, making it a promising target for drug discovery.